Login Register Cart 0
Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Measuring Mood and Anxiety Disorders by Patient Reported Outcomes in Inflammatory Bowel Disease: A Literature Review Update

Author(s): Rocco Spagnuolo*, Antonio Basile, Alessandro Corea, Francesco Salvatore Iaquinta, Nataša Milić, Patrizia Doldo, Francesco Luzza and Ludovico Abenavoli

Volume 17, Issue 3, 2022

Published on: 17 October, 2022

Page: [156 - 170] Pages: 15

DOI: 10.2174/1574887117666220628151256

Price: $65

Abstract

Background: Anxiety and depression are the most common psychological disorders found in Inflammatory Bowel Disease (IBD) patients. Accurate measuring of these disorders should be proposed for prompt management. Patient-reported outcome measurements (PROMs) allow patients to self-report their psychological symptoms.

Objective: The objective of this study is to highlight the presence of PROMs measuring anxiety and depression in IBD setting, evaluating the most used psychometric tools.

Methods: We reviewed the literature from 2010 up to September 2021. Articles on adult IBD patients assessing depression and anxiety by PROMs in English language were included.

Results: Thirty-six studies, including 11 psychometric tools were found. Hospital Anxiety and Depression Scale (21 studies), Beck Depression Inventory II (5 studies), Spielberg State-Trait Anxiety Inventory (3 studies), Patient-Reported Outcomes Measurement Information System (3 studies), Symptom Checklist-90 (2 studies), Euro Quality of Life (2 studies) mostly used psychometric tools for anxiety and depression in IBD settings.

Conclusion: Our review analyzed psychometric tools used for PROMs evaluating anxiety and depression in IBD setting. No chronological differences have emerged, all have been used in the last ten years, highlighting lack of specificity. The strong association between IBD and mood disorders suggests that clinicians should consider the evaluation of depression and anxiety as integral parts of IBD clinical care. It is essential to identify tools enabling these items to be detected better. A global view of IBD patients, accounting not only for physical but also for psychical symptoms with an early and feasible assessment of unrecognized psychiatric disorders, can have a strong impact on their management strategy.

Keywords: Inflammatory Bowel Disease, Patient-Reported Outcome Measurements (PROMs), Quality of life, Anxiety, Depression, Hospital Anxiety and Depression Scale (HADS), Patient-Reported Outcome Measurement Information System (PROMIS).

« Previous Next »
[1]
Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361(21): 2066-78.
[http://dx.doi.org/10.1056/NEJMra0804647] [PMID: 19923578]
[2]
Loftus EVJ Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126(6): 1504-17.
[http://dx.doi.org/10.1053/j.gastro.2004.01.063] [PMID: 15168363]
[3]
Burisch J, Jess T, Martinato M, Lakatos PL. The burden of inflammatory bowel disease in Europe. J Crohn’s Colitis 2013; 7(4): 322-37.
[http://dx.doi.org/10.1016/j.crohns.2013.01.010] [PMID: 23395397]
[4]
Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2017; 390(10114): 2769-78.
[http://dx.doi.org/10.1016/S0140-6736(17)32448-0] [PMID: 29050646]
[5]
Tursi A, Mocci G, Faggiani R, et al. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: A real-life multicenter, observational study in Italian primary inflammatory bowel disease centers. Ann Gastroenterol 2019; 32(4): 392-9.
[http://dx.doi.org/10.20524/aog.2019.0377] [PMID: 31263362]
[6]
Tursi A, Mocci G, Faggiani R, et al. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers. Eur J Intern Med 2019; 66: 85-91.
[http://dx.doi.org/10.1016/j.ejim.2019.06.006] [PMID: 31208827]
[7]
Larussa T, Suraci E, Marasco R, et al. Barriers and facilitators in conducting clinical trials in inflammatory bowel disease: A monocentric Italian survey. Rev Recent Clin Trials 2020; 15(2): 137-44.
[http://dx.doi.org/10.2174/1574887115666200224113520] [PMID: 32091346]
[8]
Larussa T, Flauti D, Abenavoli L, et al. The reality of patient-reported outcomes of health-related quality of life in an Italian cohort of patients with inflammatory bowel disease: Results from a cross-sectional study. J Clin Med 2020; 9(8): 9.
[http://dx.doi.org/10.3390/jcm9082416] [PMID: 32731482]
[9]
Lönnfors S, Vermeire S, Greco M, Hommes D, Bell C, Avedano L. IBD and health-related quality of life - discovering the true impact. J Crohn’s Colitis 2014; 8(10): 1281-6.
[http://dx.doi.org/10.1016/j.crohns.2014.03.005] [PMID: 24662394]
[10]
Fung KW, Xu J, Bodenreider O. The new international classification of diseases 11th edition: A comparative analysis with ICD-10 and ICD-10-CM.In: J Am Med Inform Assoc. 2020; 27: pp. 738-46.
[11]
Taft TH, Ballou S, Bedell A, Lincenberg D. Psychological considerations and interventions in inflammatory bowel disease patient care. Gastroenterol Clin North Am 2017; 46(4): 847-58.
[http://dx.doi.org/10.1016/j.gtc.2017.08.007] [PMID: 29173526]
[12]
Neuendorf R, Harding A, Stello N, Hanes D, Wahbeh H. Depression and anxiety in patients with Inflammatory Bowel Disease: A systematic review. J Psychosom Res 2016; 87: 70-80.
[http://dx.doi.org/10.1016/j.jpsychores.2016.06.001] [PMID: 27411754]
[13]
Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: A review of comorbidity and management. Inflamm Bowel Dis 2009; 15(7): 1105-18.
[http://dx.doi.org/10.1002/ibd.20873] [PMID: 19161177]
[14]
Goodhand JR, Wahed M, Mawdsley JE, Farmer AD, Aziz Q, Rampton DS. Mood disorders in inflammatory bowel disease: Relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm Bowel Dis 2012; 18(12): 2301-9.
[http://dx.doi.org/10.1002/ibd.22916] [PMID: 22359369]
[15]
Bernstein CN, Hitchon CA, Walld R, et al. Increased burden of psychiatric disorders in inflammatory bowel disease. Inflamm Bowel Dis 2019; 25(2): 360-8.
[http://dx.doi.org/10.1093/ibd/izy235] [PMID: 29986021]
[16]
Thakur ER, Sansgiry S, Kramer JR, et al. The incidence and prevalence of anxiety, depression, and post-traumatic stress disorder in a national cohort of US veterans with inflammatory bowel disease. Inflamm Bowel Dis 2020; 26(9): 1423-8.
[http://dx.doi.org/10.1093/ibd/izz280] [PMID: 31728520]
[17]
Nahon S, Lahmek P, Durance C, et al. Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18(11): 2086-91.
[http://dx.doi.org/10.1002/ibd.22888] [PMID: 22294486]
[18]
Mancina RM, Pagnotta R, Pagliuso C, et al. Gastrointestinal symptoms of and psychosocial changes in inflammatory bowel disease: A nursing-led cross-sectional study of patients in clinical remission. Medicina (Kaunas) 2020; 56(1): 56.
[http://dx.doi.org/10.3390/medicina56010045] [PMID: 31968710]
[19]
Marafini I, Longo L, Lavasani DM, et al. High frequency of undiagnosed psychiatric disorders in inflammatory bowel diseases. J Clin Med 2020; 9(5): 9.
[http://dx.doi.org/10.3390/jcm9051387] [PMID: 32397198]
[20]
Walker JR, Ediger JP, Graff LA, et al. The Manitoba IBD cohort study: A population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol 2008; 103(8): 1989-97.
[http://dx.doi.org/10.1111/j.1572-0241.2008.01980.x] [PMID: 18796096]
[21]
Marrie RA, Walld R, Bolton JM, et al. Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. Epidemiol Psychiatr Sci 2019; 28(3): 333-42.
[http://dx.doi.org/10.1017/S2045796017000579] [PMID: 29098977]
[22]
Irving P, Barrett K, Nijher M, de Lusignan S. Prevalence of depression and anxiety in people with inflammatory bowel disease and associated healthcare use: population-based cohort study. Evid Based Ment Health 2021; 24(3): 102-9.
[http://dx.doi.org/10.1136/ebmental-2020-300223] [PMID: 33785498]
[23]
Araki M, Shinzaki S, Yamada T, et al. Psychologic stress and disease activity in patients with inflammatory bowel disease: A multicenter cross-sectional study. PLoS One 2020; 15(5): e0233365.
[http://dx.doi.org/10.1371/journal.pone.0233365] [PMID: 32453762]
[24]
Rozich JJ, Holmer A, Singh S. Effect of lifestyle factors on outcomes in patients with inflammatory bowel diseases. Am J Gastroenterol 2020; 115(6): 832-40.
[http://dx.doi.org/10.14309/ajg.0000000000000608] [PMID: 32224703]
[25]
Bitton A, Dobkin PL, Edwardes MD, et al. Predicting relapse in Crohn’s disease: A biopsychosocial model. Gut 2008; 57(10): 1386-92.
[http://dx.doi.org/10.1136/gut.2007.134817] [PMID: 18390994]
[26]
Kochar B, Barnes EL, Long MD, et al. Depression is associated with more aggressive inflammatory bowel disease. Am J Gastroenterol 2018; 113(1): 80-5.
[http://dx.doi.org/10.1038/ajg.2017.423] [PMID: 29134965]
[27]
Moulton CD, Pavlidis P, Norton C, et al. Depressive symptoms in inflammatory bowel disease: An extraintestinal manifestation of inflammation? Clin Exp Immunol 2019; 197(3): 308-18.
[http://dx.doi.org/10.1111/cei.13276] [PMID: 30762873]
[28]
Ananthakrishnan AN, Gainer VS, Perez RG, et al. Psychiatric comorbidity is associated with increased risk of surgery in Crohn’s disease. Aliment Pharmacol Ther 2013; 37(4): 445-54.
[http://dx.doi.org/10.1111/apt.12195] [PMID: 23289600]
[29]
Persoons P, Vermeire S, Demyttenaere K, et al. The impact of major depressive disorder on the short- and long-term outcome of Crohn’s disease treatment with infliximab. Aliment Pharmacol Ther 2005; 22(2): 101-10.
[http://dx.doi.org/10.1111/j.1365-2036.2005.02535.x] [PMID: 16011668]
[30]
Kuźnicki P, Kempiński R, Neubauer K. The emerging role of mood disorders in inflammatory bowel diseases. Adv Clin Exp Med 2020; 29(12): 1505-10.
[http://dx.doi.org/10.17219/acem/127676] [PMID: 33389842]
[31]
Collins SM. Interrogating the gut-brain axis in the context of inflammatory bowel disease: A translational approach. Inflamm Bowel Dis 2020; 26(4): 493-501.
[http://dx.doi.org/10.1093/ibd/izaa004] [PMID: 31970390]
[32]
Ancona A, Petito C, Iavarone I, et al. The gut-brain axis in irritable bowel syndrome and inflammatory bowel disease. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 2021; 53(3): 298-305.
[http://dx.doi.org/10.1016/j.dld.2020.11.026] [PMID: 33303315]
[33]
Abautret-Daly Á, Dempsey E, Parra-Blanco A, Medina C, Harkin A. Gut-brain actions underlying comorbid anxiety and depression associated with inflammatory bowel disease. Acta Neuropsychiatr 2018; 30(5): 275-96.
[http://dx.doi.org/10.1017/neu.2017.3] [PMID: 28270247]
[34]
Frolkis AD, Vallerand IA, Shaheen A-A, et al. Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. Gut 2019; 68(9): 1606-12.
[http://dx.doi.org/10.1136/gutjnl-2018-317182] [PMID: 30337374]
[35]
Macer BJD, Prady SL, Mikocka-Walus A. Antidepressants in inflammatory bowel disease: A systematic review. Inflamm Bowel Dis 2017; 23(4): 534-50.
[http://dx.doi.org/10.1097/MIB.0000000000001059] [PMID: 28267046]
[36]
Ou G, Bressler B, Galorport C, et al. Rate of corticosteroid-induced mood changes in patients with inflammatory bowel disease: A prospective study. J Can Assoc Gastroenterol 2018; 1(3): 99-106.
[http://dx.doi.org/10.1093/jcag/gwy023] [PMID: 31294728]
[37]
Rhodes JM, Robinson R, Beales I, et al. Clinical trial: Oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. Aliment Pharmacol Ther 2008; 27(3): 228-40.
[http://dx.doi.org/10.1111/j.1365-2036.2007.03569.x] [PMID: 17988236]
[38]
Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut 2011; 60(6): 780-7.
[http://dx.doi.org/10.1136/gut.2010.221127] [PMID: 21209123]
[39]
Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 2008; 135(4): 1130-41.
[http://dx.doi.org/10.1053/j.gastro.2008.07.014] [PMID: 18706417]
[40]
Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146(1): 85-95.
[http://dx.doi.org/10.1053/j.gastro.2013.05.048] [PMID: 23735746]
[41]
Levenstein S, Prantera C, Varvo V, et al. Psychological stress and disease activity in ulcerative colitis: A multidimensional cross-sectional study. Am J Gastroenterol 1994; 89(8): 1219-25.
[PMID: 8053438]
[42]
Sandborn WJ, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR. Reinduction with certolizumab pegol in patients with relapsed Crohn’s disease: Results from the PRECiSE 4 study. Clin Gastroenterol Hepatol 2010; 8(8): 696-702.e1.
[http://dx.doi.org/10.1016/j.cgh.2010.03.024] [PMID: 20363366]
[43]
D’Haens G, Reinisch W, Colombel J-F, et al. Five-year safety data from ENCORE, a European observational safety registry for adults with Crohn’s disease treated with Infliximab [Remicade®] or conventional therapy. J Crohn’s Colitis 2017; 11(6): 680-9.
[PMID: 28025307]
[44]
Zheng P, Zeng B, Zhou C, et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol Psychiatry 2016; 21(6): 786-96.
[http://dx.doi.org/10.1038/mp.2016.44] [PMID: 27067014]
[45]
Waclawiková B, El Aidy S. Role of microbiota and tryptophan metabolites in the remote effect of intestinal inflammation on brain and depression. Pharmaceuticals (Basel) 2018; 11(3): 63.
[http://dx.doi.org/10.3390/ph11030063] [PMID: 29941795]
[46]
Carloni S, Bertocchi A, Mancinelli S, et al. Identification of a choroid plexus vascular barrier closing during intestinal inflammation. Science 2021; 374(6566): 439-48.
[http://dx.doi.org/10.1126/science.abc6108] [PMID: 34672740]
[47]
Lewis K, Marrie RA, Bernstein CN, et al. The prevalence and risk factors of undiagnosed depression and anxiety disorders among patients with inflammatory bowel disease. Inflamm Bowel Dis 2019; 25(10): 1674-80.
[http://dx.doi.org/10.1093/ibd/izz045] [PMID: 30888037]
[48]
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67(6): 361-70.
[http://dx.doi.org/10.1111/j.1600-0447.1983.tb09716.x] [PMID: 6880820]
[49]
Bernabeu P, van-der Hofstadt C, Rodríguez-Marín J, et al. Effectiveness of a multicomponent group psychological intervention program in patients with inflammatory bowel disease: A randomized trial. Int J Environ Res Public Health 2021; 18(10): 18.
[http://dx.doi.org/10.3390/ijerph18105439] [PMID: 34069621]
[50]
Goodhand JR, Kamperidis N, Sirwan B, et al. Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38(9): 1097-108.
[http://dx.doi.org/10.1111/apt.12476] [PMID: 24099471]
[51]
Knowles SR, Wilson J, Wilkinson A, et al. Psychological well-being and quality of life in Crohn’s disease patients with an ostomy: A preliminary investigation. Ostomy Cont Nurses Soc 2013; 40(6): 623-9.
[http://dx.doi.org/10.1097/01.WON.0000436670.56153.7b] [PMID: 24202226]
[52]
Gao X, Tang Y, Lei N, et al. Symptoms of anxiety/depression is associated with more aggressive inflammatory bowel disease. Sci Rep 2021; 11(1): 1440.
[http://dx.doi.org/10.1038/s41598-021-81213-8] [PMID: 33446900]
[53]
Siebert U, Wurm J, Gothe RM, et al. Predictors of temporary and permanent work disability in patients with inflammatory bowel disease: Results of the swiss inflammatory bowel disease cohort study. Inflamm Bowel Dis 2013; 19(4): 847-55.
[http://dx.doi.org/10.1097/MIB.0b013e31827f278e] [PMID: 23446333]
[54]
Vogelaar L, van’t Spijker A, van Tilburg AJP, Kuipers EJ, Timman R, van der Woude CJ. Determinants of fatigue in Crohn’s disease patients. Eur J Gastroenterol Hepatol 2013; 25(2): 246-51.
[http://dx.doi.org/10.1097/MEG.0b013e32835aba83] [PMID: 23111414]
[55]
van Langenberg DR, Gibson PR. Factors associated with physical and cognitive fatigue in patients with Crohn’s disease: A cross-sectional and longitudinal study. Inflamm Bowel Dis 2014; 20(1): 115-25.
[http://dx.doi.org/10.1097/01.MIB.0000437614.91258.70] [PMID: 24297056]
[56]
Bernstein CN, Zhang L, Lix LM, et al. The validity and reliability of screening measures for depression and anxiety disorders in inflammatory bowel disease. Inflamm Bowel Dis 2018; 24(9): 1867-75.
[http://dx.doi.org/10.1093/ibd/izy068] [PMID: 29668911]
[57]
Herrmann C. International experiences with the Hospital Anxiety and Depression Scale--a review of validation data and clinical results. J Psychosom Res 1997; 42(1): 17-41.
[http://dx.doi.org/10.1016/S0022-3999(96)00216-4] [PMID: 9055211]
[58]
Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes 2003; 1(1): 29.
[http://dx.doi.org/10.1186/1477-7525-1-29] [PMID: 12914662]
[59]
Bennebroek Evertsz’ F, Thijssens NAM, Stokkers PCF, et al. Do inflammatory bowel disease patients with anxiety and depressive symptoms receive the care they need? J Crohn’s Colitis 2012; 6(1): 68-76.
[http://dx.doi.org/10.1016/j.crohns.2011.07.006] [PMID: 22261530]
[60]
Bessissow T, Van Keerberghen C-A, Van Oudenhove L, et al. Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls. J Crohn’s Colitis 2013; 7(11): e580-7.
[http://dx.doi.org/10.1016/j.crohns.2013.04.011] [PMID: 23664621]
[61]
Bryant RV, van Langenberg DR, Holtmann GJ, Andrews JM. Functional gastrointestinal disorders in inflammatory bowel disease: impact on quality of life and psychological status. J Gastroenterol Hepatol 2011; 26(5): 916-23.
[http://dx.doi.org/10.1111/j.1440-1746.2011.06624.x] [PMID: 21214889]
[62]
Cámara RJA, Schoepfer AM, Pittet V, Begré S, von Känel R. Mood and nonmood components of perceived stress and exacerbation of Crohn’s disease. Inflamm Bowel Dis 2011; 17(11): 2358-65.
[http://dx.doi.org/10.1002/ibd.21623] [PMID: 21287671]
[63]
Häuser W, Janke K-H, Klump B, Hinz A. Anxiety and depression in patients with inflammatory bowel disease: comparisons with chronic liver disease patients and the general population. Inflamm Bowel Dis 2011; 17(2): 621-32.
[http://dx.doi.org/10.1002/ibd.21346] [PMID: 20848528]
[64]
Iglesias-Rey M, Barreiro-de Acosta M, Caamaño-Isorna F, et al. How do psychological variables influence coping strategies in inflammatory bowel disease? J Crohn’s Colitis 2013; 7(6): e219-26.
[http://dx.doi.org/10.1016/j.crohns.2012.09.017] [PMID: 23083699]
[65]
Iglesias-Rey M, Barreiro-de Acosta M, Caamaño-Isorna F, et al. Psychological factors are associated with changes in the health-related quality of life in inflammatory bowel disease. Inflamm Bowel Dis 2014; 20(1): 92-102.
[PMID: 24193152]
[66]
Kim ES, Cho KB, Park KS, et al. Predictive factors of impaired quality of life in Korean patients with inactive inflammatory bowel disease: Association with functional gastrointestinal disorders and mood disorders. J Clin Gastroenterol 2013; 47(4): e38-44.
[http://dx.doi.org/10.1097/MCG.0b013e318266fff5] [PMID: 23090047]
[67]
Knowles SR, Wilson JL, Connell WR, Kamm MA. Preliminary examination of the relations between disease activity, illness perceptions, coping strategies, and psychological morbidity in Crohn’s disease guided by the common sense model of illness. Inflamm Bowel Dis 2011; 17(12): 2551-7.
[http://dx.doi.org/10.1002/ibd.21650] [PMID: 21425208]
[68]
Selinger CP, Lal S, Eaden J, et al. Better disease specific patient knowledge is associated with greater anxiety in inflammatory bowel disease. J Crohn’s Colitis 2013; 7(6): e214-8.
[http://dx.doi.org/10.1016/j.crohns.2012.09.014] [PMID: 23062330]
[69]
Bennebroek Evertsz’ F, Sprangers MAG, de Vries LM, et al. I am a total failure: Associations between beliefs and anxiety and depression in patients with inflammatory bowel disease with poor mental quality of life. Behav Cogn Psychother 2020; 48(1): 91-102.
[http://dx.doi.org/10.1017/S1352465819000444] [PMID: 31423955]
[70]
Guloksuz S, Wichers M, Kenis G, et al. Depressive symptoms in Crohn’s disease: Relationship with immune activation and tryptophan availability. PLoS One 2013; 8(3): e60435.
[http://dx.doi.org/10.1371/journal.pone.0060435] [PMID: 23544139]
[71]
Jedel S, Hoffman A, Merriman P, et al. A randomized controlled trial of mindfulness-based stress reduction to prevent flare-up in patients with inactive ulcerative colitis. Digestion 2014; 89(2): 142-55.
[http://dx.doi.org/10.1159/000356316] [PMID: 24557009]
[72]
Lima FD, Ribeiro TC da R, Chebli LA, et al. Mood swings in patients with Crohn’s disease: Incidence and associated factors. Rev Assoc Med Bras 2012; 58(4): 481-8.
[http://dx.doi.org/10.1016/S0104-4230(12)70233-6] [PMID: 22930029]
[73]
Zhang CK, Hewett J, Hemming J, et al. The influence of depression on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19(8): 1732-9.
[http://dx.doi.org/10.1097/MIB.0b013e318281f395] [PMID: 23669400]
[74]
Hunt MG, Loftus P, Accardo M, Keenan M, Cohen L, Osterman MT. Self-help cognitive behavioral therapy improves health-related quality of life for inflammatory bowel disease patients: A randomized controlled effectiveness trial. J Clin Psychol Med Settings 2020; 27(3): 467-79.
[http://dx.doi.org/10.1007/s10880-019-09621-7] [PMID: 31025253]
[75]
Moullec G, Plourde A, Lavoie KL, Suarthana E, Bacon SL. Beck depression inventory II: Determination and comparison of its diagnostic accuracy in cardiac outpatients. Eur J Prev Cardiol 2015; 22(5): 665-72.
[http://dx.doi.org/10.1177/2047487314527851] [PMID: 24618475]
[76]
Westhoff-Bleck M, Winter L, Aguirre Davila L, et al. Diagnostic evaluation of the hospital depression scale (HADS) and the Beck depression inventory II (BDI-II) in adults with congenital heart disease using a structured clinical interview: Impact of depression severity. Eur J Prev Cardiol 2020; 27(4): 381-90.
[http://dx.doi.org/10.1177/2047487319865055] [PMID: 31349778]
[77]
Wang Y-P, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: A comprehensive review. Rev Bras Psiquiatr 2013; 35(4): 416-31.
[http://dx.doi.org/10.1590/1516-4446-2012-1048] [PMID: 24402217]
[78]
Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Arthritis Care Res (Hoboken) 2011; 63(S11) (Suppl. 11): S467-72.
[http://dx.doi.org/10.1002/acr.20561] [PMID: 22588767]
[79]
Ananthakrishnan AN, Long MD, Martin CF, Sandler RS, Kappelman MD. Sleep disturbance and risk of active disease in patients with Crohn’s disease and ulcerative colitis. Clin Gastroenterol Hepatol 2013; 11(8): 965-71.
[http://dx.doi.org/10.1016/j.cgh.2013.01.021] [PMID: 23376797]
[80]
Kappelman MD, Long MD, Martin C, et al. Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12(8): 1315-23.e2.
[http://dx.doi.org/10.1016/j.cgh.2013.10.019] [PMID: 24183956]
[81]
Bojic D, Bodger K, Travis S. Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data. J Crohn’s Colitis 2017; 11 (Suppl. 2): S576-85.
[PMID: 27797917]
[82]
Leone D, Gilardi D, Corrò BE, et al. Psychological characteristics of inflammatory bowel disease patients: A comparison between active and nonactive patients. Inflamm Bowel Dis 2019; 25(8): 1399-407.
[http://dx.doi.org/10.1093/ibd/izy400] [PMID: 30689871]
[83]
Cohen BL, Zoëga H, Shah SA, et al. Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity. Aliment Pharmacol Ther 2014; 39(8): 811-22.
[http://dx.doi.org/10.1111/apt.12659] [PMID: 24612278]
[84]
Lahat A, Lang A, Ben-Horin S. Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: A pilot prospective study. Digestion 2012; 85(1): 1-8.
[http://dx.doi.org/10.1159/000332079] [PMID: 22095142]
[85]
Ananthakrishnan AN, Khalili H, Pan A, et al. Association between depressive symptoms and incidence of Crohn’s disease and ulcerative colitis: Results from the Nurses’ Health Study. Clin Gastroenterol Hepatol 2013; 11(1): 57-62.
[http://dx.doi.org/10.1016/j.cgh.2012.08.032] [PMID: 22944733]
[86]
Bokemeyer B, Hardt J, Hüppe D, et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: An online IBD registry. J Crohn’s Colitis 2013; 7(5): 355-68.
[http://dx.doi.org/10.1016/j.crohns.2012.02.014] [PMID: 22503168]
[87]
Mountifield R, Bampton P, Prosser R, Mikocka-Walus A, Andrews JM. Colon cancer surveillance in inflammatory bowel disease: Unclear gain but no psychological pain? Intern Med J 2014; 44(2): 131-8.
[http://dx.doi.org/10.1111/imj.12317] [PMID: 24383700]
[88]
Wynne B, McHugh L, Gao W, et al. Acceptance and commitment therapy reduces psychological stress in patients with inflammatory bowel diseases. Gastroenterology 2019; 156(4): 935-945.e1.
[http://dx.doi.org/10.1053/j.gastro.2018.11.030] [PMID: 30452919]
[89]
Prins MA, Verhaak PFM, Bensing JM, van der Meer K. Health beliefs and perceived need for mental health care of anxiety and depression--the patients’ perspective explored. Clin Psychol Rev 2008; 28(6): 1038-58.
[http://dx.doi.org/10.1016/j.cpr.2008.02.009] [PMID: 18420323]
[90]
Collins KA, Westra HA, Dozois DJA, Burns DD. Gaps in accessing treatment for anxiety and depression: Challenges for the delivery of care. Clin Psychol Rev 2004; 24(5): 583-616.
[http://dx.doi.org/10.1016/j.cpr.2004.06.001] [PMID: 15325746]
[91]
Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: Results from the national comorbidity survey replication. Arch Gen Psychiatry 2005; 62(6): 629-40.
[http://dx.doi.org/10.1001/archpsyc.62.6.629] [PMID: 15939840]
[92]
Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: Medical treatment. J Crohn’s Colitis 2020; 14(1): 4-22.
[http://dx.doi.org/10.1093/ecco-jcc/jjz180] [PMID: 31711158]
[93]
Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn’s Colitis 2017; 11(6): 649-70.
[http://dx.doi.org/10.1093/ecco-jcc/jjx008] [PMID: 28158501]
[94]
Kemp K, Dibley L, Chauhan U, et al. Second N-ECCO consensus statements on the european nursing roles in caring for patients with Crohn’s disease or ulcerative colitis. J Crohn’s Colitis 2018; 12(7): 760-76.
[http://dx.doi.org/10.1093/ecco-jcc/jjy020] [PMID: 29509882]
[95]
Spagnuolo R, Corea A, Napolitano D, et al. Nursing-sensitive outcomes in adult inflammatory bowel disease: A systematic review. J Adv Nurs 2021; 77(5): 2248-66.
[http://dx.doi.org/10.1111/jan.14744] [PMID: 33426709]
[96]
Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68 (Suppl. 3): s1-s106.
[http://dx.doi.org/10.1136/gutjnl-2019-318484] [PMID: 31562236]
[97]
Patrick DL, Burke LB, Powers JH, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007; 10 (Suppl. 2): S125-37.
[http://dx.doi.org/10.1111/j.1524-4733.2007.00275.x] [PMID: 17995471]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy